Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

NCT06067802 is registered in ClinicalTrials.gov with Jerry Vockley, MD, PhD as lead sponsor.

NCT NCT06067802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Escalating Dose, Open Label Study to Evaluate the Safety of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Lead sponsor
Jerry Vockley, MD, PhD
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2026
Completion date
March 31, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medium-chain acyl-coa dehydrogenase deficiency